Gene therapy clinical trials worldwide to 2012 - an update

Journal of Gene Medicine

Volumn 15, Issue 2, 2013, Pages 65-77

  Ginn, Samantha L ^a,b   Alexander, Ian E ^a,c   Edelstein, Michael L ^d   Abedi, Mohammad R ^e   Wixon, Jo ^f  

^a CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f John Wiley and Sons   (United Kingdom)

Author keywords

Clinical trials; Database; Gene therapy; The Journal of Gene Medicine; Worldwide

Indexed keywords

6 O BENZYLGUANINE; ADENOSINE DEAMINASE; ADENOVIRUS VECTOR; ALKYLATING AGENT; ANTIGEN; BRCA1 PROTEIN; BUSULFAN; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; CYTOKINE; CYTOTOXIC AGENT; DNA VACCINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FUSED IN SARCOMA PROTEIN; GANCICLOVIR; GROWTH FACTOR; LENTIVIRUS VECTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR; PRODRUG; PROTEIN P53; RETROVIRUS VECTOR; RNA; THYMIDINE KINASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; ADENOVIRUS INFECTION; ADRENOLEUKODYSTROPHY; ANGIOGENESIS; BETA THALASSEMIA; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA; CARDIOVASCULAR GENE THERAPY; CELL BASED GENE THERAPY; CHRONIC GRANULOMATOUS DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; DEGENERATIVE DISEASE; DNA METHYLATION; DNA MODIFICATION; GENE DELIVERY SYSTEM; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENE VECTOR; GENETIC TRANSCRIPTION; GEOGRAPHIC DISTRIBUTION; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; IN VIVO GENE TRANSFER; LEBER CONGENITAL AMAUROSIS; LIMB ISCHEMIA; LIPOSOMAL GENE DELIVERY SYSTEM; MELANOMA; METACHROMATIC LEUKODYSTROPHY; MUTAGENESIS; NEUROLOGIC DISEASE; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; REVIEW; SUICIDE GENE; T CELL LEUKEMIA; T LYMPHOCYTE; TETANUS; TUMOR LYSIS SYNDROME; TUMOR SUPPRESSOR GENE; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; VIRUSES;

EID: 84874346554     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2698     Document Type: Review

References (88)

1. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-2245.
2. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
3. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-3142.
4. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 18: 3143-3150.
5. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
6. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193.
7. Ginn SL, Curtin JA, Kramer B, et al. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia. Med J Aust 2005; 182: 458-463.
8. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
9. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363: 355-364.
10. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
11. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
12. Herzog RW. Gene therapy for SCID-X1: round 2. Mol Ther 2010; 18: 1891.
13. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475-480.
14. Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 2002; 8: 423-425.
15. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
16. Ferrua F, Brigida I, Aiuti A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr Opin Allergy Clin Immunol 2010; 10: 551-556.
17. Gaspar HB, Aiuti A, Porta F, et al. How I treat ADA deficiency. Blood 2009; 114: 3524-3532.
18. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
19. Ogino S, Gulley ML, den Dunnen JT, et al. Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. J Mol Diagn 2007; 9: 1-6.
20. Gaspar HB. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin North Am 2010; 30: 221-236.
21. Engel BC, Podsakoff GM, Ireland JL, et al. Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report. Blood 2007; 109: 503-506.
22. Sokolic R, Kesserwan C, Candotti F. Recent advances in gene therapy for severe congenital immunodeficiency diseases. Curr Opin Hematol 2008; 15: 375-380.
23. Kohn DB. Update on gene therapy for immunodeficiencies. Clin Immunol 2010; 135: 247-254.
24. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Haematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823.
25. Cartier N, Hacein-Bey Abina S, Bartholomae C, et al. Haematopoietic stem cell gene therapy for X-linked adrenoleukodystrophy. Hum Gene Ther 2012; 23: A17.
26. Montini E, Biffi A, Calabria A, et al. Integration site analysis in a clinical trial of lentiviral vector based haematopoietic stem cell gene therapy for meatchromatic leukodystrophy. Hum Gene Ther 2012; 23: A13.
27. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
28. Robbins PF, Morgan RA, Feldman SA, et al. Tumour regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-924.
29. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumour effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
30. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl J Med 2011; 365: 725-733.
31. Adair JE, Beard BC, Trobridge GD, et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med 2012; 4: 133ra57.
32. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008; 105: 15112-15117.
33. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008; 19: 979-990.
34. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239.
35. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 2009; 361: 725-727.
36. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010; 18: 643-650.
37. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374: 1597-1605.
38. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4: 120ra15.
39. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
40. European Society for Gene Therapy. One of three successfully treated CGD patients in a Swiss-German gene therapy trial died due to his underlying disease. J Gene Med 2006; 8: 1435.
41. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
42. Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009; 114: 2619-2622.
43. Kang EM, Choi U, Theobald N, et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010; 115: 783-791.
44. Kang HJ, Bartholomae CC, Paruzynski A, et al. Retroviral gene therapy for X-linked chronic granulomatous disease: results from Phase I/II trial. Mol Ther 2011; 19: 2092-2101.
45. Grez M, Reichenbach J, Schwable J, et al. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 2011; 19: 28-35.
46. Santilli G, Almarza E, Brendel C, et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011; 19: 122-132.
47. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467: 318-322.
48. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. New Engl J Med 2010; 363: 1918-1927.
49. Klein C. Effective gene therapy for children with Wiskott-Aldrich syndrome. 2010. http://wwwidw-onlinede/pages/de/news396307%3E2010 [4 February 2013].
50. Persons DA, Baum C. Solving the problem of gamma-retroviral vectors containing long-terminal repeats. Mol Ther 2011; 19: 229-231.
51. NIH Recombinant DNA Advisory Committee (RAC). nd. http://oba.od.nih.gov/rdna_rac/rac_about.html [4 February 2013].
52. GTAC summary table of UK gene therapy research. 2010. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/GTAC/Publications/index.htm [4 February 2013].
53. Belgian Biosafety server gene therapy clinical trials information. 2005. http://www.biosafety.be/GT/regulatory/GTtrials.html [4 February 2013].
54. Internet Portal of the German Clinical trials register (DRKS). 2011. https://drks-neu.uniklinik-freiburg.de/drks_web/ [4 February 2013].
55. Swiss Expert Committee for Biosafety (EFBS/CFSB) gene therapy clinical trials information. 2010. http://www.efbs.admin.ch/en/topics/gene-therapy/index.html [4 February 2013].
56. Dutch Ministry of Housing, Spatial Planning and the Environment (VROM) GGO office. nd. http://bggo.rivm.nl/Paginas/vdb.htm [4 February 2013].
57. AFSSAPS public clinical trials database. 2009. https://icrepec.afssaps.fr/Public/index.php [4 February 2013].
58. European Community clinical trials database (EudraCT). 2013. http://eudract.emea.europa.eu/ [4 February 2013].
59. European Commission Genetically Modified organisms (EudraCT). 2013. http://gmoinfo.jrc.ec.europa.eu/gmo_browse.aspx [4 February 2013].
60. Australian New Zealand Clinical Trials Registry (EudraCT). 2013. http://www.anzctr.org.au/default.aspx [4 February 2013].
61. West China Medical School's Chinese Clinical Trials Registry. 2011. http://www.chictr.org/en/ [4 February 2013].
62. Japan National Institute of Public Health Clinical Trial Search. 2002. http://rctportal.niph.go.jp/en/index [4 February 2013].
63. World Health Organization International Clinical Trials Registry Platform. 2010. http://apps.who.int/trialsearch/ [4 February 2013].
64. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007; 9: 833-842.
65. Manno CS, Arruda VR, Pierce GF, et al. Successful transduction of liver in haemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-7.
66. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009; 114: 2077-2086.
67. Sack BK, Herzog RW. Evading the immune response upon in vivo gene therapy with viral vectors. Curr Opin Mol Ther 2009; 11: 493-503.
68. Nathwani A, Tuddenham E, Rosales C, et al. Early clinical trial results following administration of a low dose of a novel self complementary adeno-associated viral vector encoding human factor IX in two subjects with severe haemophilia B. American Society of haematology Annual Meeting. Blood 2010; 116: 114.
69. Basner-Tschakarjan E, Mingozzi F, Chen Y, et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study of haemophilia B. Mol Ther 2011; 19: S230.
70. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in haemophilia B. New Engl J Med 2011; 365: 2357-2365.
71. Brown BD, Venneri MA, Zingale A, et al. Endogenous microRNA regulation suppresses transgene expression in haematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12: 585-591.
72. Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of haemophilia B mice. Blood 2007; 110: 4144-4152.
73. Annoni A, Brown BD, Cantore A, et al. In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunological tolerance. Blood 2009; 114: 5152-5161.
74. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
75. Takahashi K, Okita K, Nakagawa M, et al. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007; 2: 3081-3089.
76. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
77. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7: 618-630.
78. Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009; 27: 2667-2674.
79. Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B 2009; 85: 348-362.
80. Kim D, Kim C-H, Moon J-I, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472-476.
81. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324: 797-801.
82. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci 2008; 105: 5856-5861.
83. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with ips cells generated from autologous skin. Science 2007; 318: 1920-1923.
84. Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460: 53-59.
85. Kazuki Y, Hiratsuka M, Takiguchi M, et al. Complete genetic correction of iPS cells from Duchenne muscular dystrophy. Mol Ther 2009; 18: 386-393.
86. Forrest S, Meloni PL, Muntoni F, et al. Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations. Neuromuscul Disord 2010; 20: 810-816.
87. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918-928.
88. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595-605.